Ganitumab
- Generic Name
- Ganitumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 905703-97-1
- Unique Ingredient Identifier
- CK1441RCZ8
- Background
Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04199026
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Palbociclib + Ganitumab In Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04129151
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 14
- Registration Number
- NCT03041701
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma
- Conditions
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT03029481
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DoxorubicinDrug: Doxorubicin HydrochlorideDrug: EtoposideDrug: Etoposide PhosphateRadiation: External Beam Radiation TherapyDrug: IfosfamideBiological: GanitumabRadiation: Stereotactic RadiosurgeryProcedure: Therapeutic Surgical ProcedureDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 312
- Registration Number
- NCT02306161
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT00788957
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.